Posts tagged Hatch-Waxman Act.
Blogs
3 minute read
Since the enactment of the Hatch-Waxman Act in 1984, courts have held that brand companies can sue generics wherever they plan on making sales, which is everywhere in the U.S. In practice, most suits have been filed in Delaware and New Jersey, with suits against multiple generic companies over the same drug consolidated in one proceeding.
In November 2020, the Federal Circuit upended this settled practice when it issued its opinion in Valeant Pharmaceuticals v. Mylan Pharmaceuticals, No. 19-2402 (Fed. Cir. 2020), holding that venue is not established by contemplated future acts of ...
Blog Editors
Recent Updates
- Watch: How to Protect Your Business from a Counterparty's Financial Crisis – Speaking of Litigation
- First DOJ DEI False Claims Act Investigation Settlement Fetches $17 Million
- DOJ Creates National Fraud Enforcement Division: What It Means for Fraud Enforcement in America
- State AGs in Action: Health Care Enforcement in 2026 – Speaking of Litigation Video Podcast
- The DOJ’s New Corporate Enforcement Policy: A Familiar but Now Nationally Unified Framework for Voluntary Self-Disclosure